Skip to main content

New story in Health from Time: As the First Coronavirus Vaccine Human Trials Begin, Manufacturer is Already Preparing To Scale Production to Millions



Last week, the first volunteers in a study of an experimental COVID-19 vaccine received their first doses, and the vaccine’s developer, Moderna Therapeutics, is already thinking ahead. Although testing on the vaccine will take at least a year to complete, the work could provide valuable information about how the immune system can fight coronaviruses and could give scientists a head start if any new outbreaks of the virus were to occur.

Non-essential staff at Moderna Therapeutics’ manufacturing facility, in Norwood, Mass., including president Dr. Stephen Hoge, are working from home as recommended by public health officials, but those involved in manufacturing what may be the first vaccine against the novel coronavirus are ready to scale up production if the first phase of testing on the vaccine shows that it’s safe.

The vaccine will be studied first in a group of 45 healthy volunteers, who have not been infected with SARS-CoV-2, the virus that causes COVID-19. In this group, scientists are looking to see if the shots are safe, and to test three different dosages to see which seems to activate the strongest immune response. If these initial subjects don’t develop any severe side effects or reactions, then researchers will recruit hundreds more healthy volunteers to confirm those results,

For the first phase, Moderna shipped hundreds of vials of the test vaccine to the National Institutes of Health (NIH), which is overseeing the study in multiple centers in the US. For the next, says Hoge, “it will be several fold, maybe five-fold larger than the first phase. We are talking thousands of vials.”

And if the vaccine proves not just safe, but also successful, the company is preparing for an anticipated “incredible demand to scale up the vaccine very, very quickly,” Hoge says, “we have already started to do work to scale up to producing millions of doses.”

That’s made possible, in part, by the non-traditional technology used to make this particular vaccine. Moderna uses mRNA, a genetic form of the virus’ genome, in its vaccine. When it’s injected into people, cells then process it so immune cells can recognize it and target it for destruction. Unlike the processes used to make most traditional vaccines, this method does not require growing huge amounts of the virus, which is time-consuming.

It’s also why the vaccine was developed in record time. Chinese researchers first posted the genetic sequence of SARS-CoV-2 in mid-January, and by Feb. 7, Moderna had vials of the vaccine ready for the standards-testing needed before the treatment could be cleared for human trials. By the last week of February, that was completed and the company sent vials to NIH for further review by its scientists. Then both Moderna and NIH filed for a request to the Food and Drug Administration, which regulates trials of experimental therapies, to start injecting the vaccine in people for human testing.

Hogue is hopeful that his team can continue to shave valuable time off the process while producing a safe and effective vaccine. “The original goal when Dr. Anthony Fauci [director of the NIH’s National Institute of Allergy and Infectious Diseases] first announced the vaccine, was to get it into humans in roughly three months. We managed to do that in 63 days, so we already demonstrated the ability to move a little faster than expectations,” he says. “We have an ethical responsibility to build the data and show the vaccine is safe and effective, and to do that in a sequential way. Still, every chance we have to continue to demonstrate that we can pull the timeline in, we will take.”

Testing on patients who have contracted the virus may still be months away, and Fauci predicts that the trials may not conclude for another 12-18 months. But in the meanwhile, every week, day and minute count. “From the very beginning, this was a race, a race against the virus,” says Hoge. “If there is anything we learned in the past month, it’s that we need to keep pressing every time advantage that we can.”

Labels:

Popular posts from this blog

New story in Health from Time: Here’s How Quickly Coronavirus Is Spreading in Your State

The novel coronavirus pandemic is a global crisis, a national emergency and a local nightmare. But while a great deal of the focus in the U.S. has been on the federal government’s response, widely criticized as slow and halting , the picture on the ground remains very different in different parts of the country. A TIME analysis of the per capita spread of the epidemic in all 50 states and Washington, D.C. found considerable range in the rate of contagion, and, in some parts of the country, a significant disparity compared to the national figure. The U.S., unlike nations such as South Korea and now Italy , has yet to show signs of bringing the runaway spread of the virus under control. However, while no single state is yet showing strong signs of bending the curve , some are faring much worse than others. The following graphic plots the rise in the total confirmed cases of COVID-19 per 100,000 residents in each state, plotted by the day that each state reported its first case.
Read more

New story in Health from Time: We Need to Take Care of the Growing Number of Long-term COVID-19 Patients

On July 7, 2020, the Boston Red Sox pitcher Eduardo Rodriguez tested positive for the new coronavirus. He was scheduled to start Opening Day for the Sox, but the virus had other plans— damaging Rodriguez’s heart and causing a condition called myocarditis (inflammation of the heart muscle). Now the previously fit 27-year old ace left-hander must sit out the 2020 season to recover. Rodriguez is not alone in having heart damage from SARS-CoV-2, the virus that causes COVID-19. In a new study done in Germany, researchers studied the hearts of 100 patients who had recently recovered from COVID-19. The findings were alarming: 78 patients had heart abnormalities, as shown by a special kind of imaging test that shows the heart’s structure (a cardiac MRI), and 60 had myocarditis. These patients were mostly young and previously healthy . Several had just returned from ski trips. While other studies have shown a lower rate of heart problems—for example, a study of 416 patients hosp
Read more

New story in Health from Time: U.S. Inmates ‘Mistakenly’ Received COVID-19 Stimulus Checks. Now, the IRS Wants That Money Back

(BOISE, Idaho) — Hundreds of thousands of dollars in coronavirus relief payments have been sent to people incarcerated across the United States, and now the IRS is asking state officials to help claw back the cash that the federal tax agency says was mistakenly sent. The legislation authorizing the payments during the pandemic doesn’t specifically exclude jail or prison inmates, and the IRS has refused to say exactly what legal authority it has to retrieve the money. On its website, it points to the unrelated Social Security Act, which bars incarcerated people from receiving some types of old-age and survivor insurance benefit payments. “I can’t give you the legal basis. All I can tell you is this is the language the Treasury and ourselves have been using,” IRS spokesman Eric Smith said. “It’s just the same list as in the Social Security Act.” Read more: ‘A Double Whammy.’ Those Who Most Need The $1,200 Stimulus Checks May Wait the Longest To Get Them Tax attorney Kell
Read more